Substance

Stimulants

Publications

Ageing and older people who use illicit opioids, cocaine or methamphetamine: a scoping review and literature map

Zolopa C., Høj S., Minoyan N., Bruneau J., Makarenko I., Larney S., Addiction, 2022

Retrospective Cohort Study Examining the Correlates of Reported Lifetime Stimulant Use in Persons Diagnosed With Infectious Syphilis in Alberta, Canada, 2018 to 2019

Raval M, Gratrix J, Plitt S, Niruban J, Smyczek P, Dong K, Singh AE., Sex Transm Dis. 2022

The practice and embodiment of “goofballs”: A qualitative study exploring the co-injection of methamphetamines and opioids

Ivsins A, Fleming T, Barker A, Mansoor M, Thakarar K, Sue K, McNeil R., Int J Drug Policy. 2022

Crack cocaine use frequency is associated with HIV disease severity independent of antiretroviral therapy exposure: a prospective cohort study

Macmadu A, Reddon H, Marshall BDL, Fairbairn N, Nolan S, Socías ME, Milloy MJ., AIDS Behav. 2022

Predictors of crystal methamphetamine use initiation or re-initiation among people receiving opioid agonist therapy: A prospective cohort study

Cui Z, Hayashi K, Bach P, Dong H, Milloy MJ, Kerr T., Drug Alcohol Depend. 2022

Opioid agonist therapy engagement and crystal methamphetamine use: The impact of unregulated opioid use in Vancouver, Canada

Cui Z, Bach P, Ti L, Hayashi K, Morgan J, Milloy MJ, Kerr T., Int J Drug Policy. 2022

Trends in cocaine and crystal methamphetamine injection over time in a Canadian setting between 2008 and 2018

Bach P, Ti L, Hayashi K, Cui Z, Milloy MJ, Fairbairn N., J Subst Use Addict Treat. 2023

Crystal methamphetamine use and methadone maintenance treatment dissatisfaction: A prospective cohort study in Vancouver, Canada

Cui Z, Hayashi K, Bach P, Milloy MJ, Kerr T., J Subst Use Addict Treat. 2023

RE: Incorporating prescription psychostimulants into the continuum of care for people with stimulant use disorder in Canada

Elefante J, Nolan S, Bach P, CMAJ, 2023

Cannabis use to manage stimulant cravings among people who use unregulated drugs

Reddon H, Socias ME, DeBeck K, Hayashi K, Walsh Z, Milloy MJ., Addict Behav. 2024

Navigating Evidence, Challenges, and Caution in the Treatment of Stimulant Use Disorders

Bahji A, Danilewitz M, Crockford D., Brain Sci. 2023

Vigilance needed with methamphetamine-associated psychosis

Elefante RJO, Nolan S, Bach PJ., CMAJ. 2023

Evidence base to support using prescribed psychostimulants to treat psychostimulant use disorder is limited

Bahji A, Danilewitz M, George TP, Dhaliwal A, Crockford DN., CMAJ. 2023

Modeling as Visioning: Exploring the Impact of Criminal Justice Reform on Health of Populations with Substance Use Disorders

Martin N.K., Beletsky L., Linas B.P., Bayoumi A., Pollack H., Larney S., Journal of Urban Health, 2023

Efficacy and Safety of Four Psychedelic-Assisted Therapies for Adults with Symptoms of Depression, Anxiety, and Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis

Bahji A, Lunsky I, Gutierrez G, Vazquez G. , J Psychoactive Drugs. 2025

Bupropion for treatment of amphetamine-type stimulant use disorder: A systematic review and meta-analysis of placebo-controlled randomized clinical trials

Bakouni H., Sharafi H., Bahremand A., Drouin S., Ziegler D., Bach P., Le Foll B., Schütz C.G., Tardelli V., Ezard N., Siefried K., Jutras-Aswad D., Drug and Alcohol Dependence, 2023

Bupropion for treatment of amphetamine-type stimulant use disorder: A systematic review and meta-analysis of placebo-controlled randomized clinical trials

Bakouni H., Sharafi H., Bahremand A., Drouin S., Ziegler D., Bach P., Le Foll B., Schütz C.G., Tardelli V., Ezard N., Siefried K., Jutras-Aswad D., Drug and Alcohol Dependence, 2023

Sexualized substance use among gbMSM: Their perspectives on their intervention needs and counsellor competencies

Blanchette M., Flores‑Aranda J., Bertrand K., Lemaître A., Jauffret‑Roustide M., Goyette M., Journal of Substance Use and Addiction Treatment, 2024

Sex and gender differences in hepatitis C virus risk, prevention, and cascade of care in people who inject drugs: systematic review and meta-analysis

Levinsson A, Zolopa C, Vakili F, Udhesister S, Kronfli N, Maheu-Giroux M, Bruneau J, Valerio H, Bajis S, Read P, Martró E, Boucher L, Morris L, Grebely J, Artenie A, Stone J, Vickerman P, Larney S., EClinicalMedicine, 2024

Efficacy and Safety of Modafinil for Treatment of Amphetamine-Type Stimulant Use Disorder: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials

Elkrief L., Sharafi H., Bakouni H., McAnulty C., Bastien G., Dubreucq S., Garel N., Trépanier A., Ziegler D., Jutras-Aswad D., Canadian Journal of Psychiatry, 2024

The effect of Montreal’s supervised consumption sites on injection-related infections among people who inject drugs: An interrupted time series

Lim J., Panagiotoglou D., PLoS ONE, 2024

Correction: Economic evaluation of the effect of needle and syringe programs on skin, soft tissue, and vascular infections in people who inject drugs: a microsimulation modelling approach

Lim J., Russell W.A., El-Sheikh M., Buckeridge D.L., Panagiotoglou D., Harm Reduction Journal, 2024

Trends in toxicological findings in unintentional opioid or stimulant toxicity deaths in Québec, Canada, 2012–2021: has Québec entered a new era of drug-related deaths?

Do U., Perron P.-A., Bruneau J., Larney S., Drug and Alcohol Review, 2024

Impact of baseline methamphetamine/amphetamine use on discontinuation of methadone and buprenorphine/naloxone among people with prescription-type opioid use disorder in Canada

Langlois J, Fairbairn N, Jutras-Aswad D, Le Foll B, Lim R, Socías ME., Am J Addict. 2024

Characterising methamphetamine/amphetamine use among opioid agonist therapy-seeking adults with prescription-type opioid use disorder in Canada

Langlois J, Fairbairn N, Jutras-Aswad D, Le Foll B, Lim R, Socías ME., Drug Alcohol Rev. 2024

Illicit drug toxicity from opioid, stimulant or sedative use in adolescents: results of a Canadian one‑time cross‑sectional study

Matthew Carwana, Eva Moore, Helia Shariati, Hasina Samji, Nicholas Chadi, Paediatrics & Child Health, 2025

Is Naltrexone Effective and Safe for Treating Amphetamine-Type Stimulant Use Disorder? A Systematic Review and Meta-analysis

Bastien G, McAnulty C, Sharafi H, Mahroug A, Elkrief L, Ziegler D, Dubreucq S, Juteau LC, Jutras-Aswad D., J Addict Med. 2025

Binge Drug Injection in a Cohort of People Who Inject Drugs in Montreal: Characterizing the Substances and Social Contexts Involved

Nanor Minoyan, Stine Bordier Høj, Didier Jutras‑Aswad, Sarah Larney, Valérie Martel‑Laferrière, Marie‑Pierre Sylvestre, Julie Bruneau, International Journal of Mental Health and Addiction, 2025

Association between prescribed stimulant medications and overdose among individuals receiving opioid agonist therapy: A retrospective cohort study from British Columbia, Canada

Young S, Fairbairn N, Cui Z, Bach P, Mok WY, Budau J, Slaunwhite A, Ti L, Hayashi K, Nolan S., Addiction. 2025

A protocol for high-dose lisdexamfetamine and contingency management, alone or in combination, for the treatment of methamphetamine use disorder: The ASCME study

Bach P, Le Foll B, Davidson S, de Kiewit A, Bakouni H, Poulin G, Ghosh M, Jutras-Aswad D., Contemp Clin Trials. 2025

Comparative Effectiveness of Buprenorphine/Naloxone and Methadone on Methamphetamine/Amphetamine Use Among People with Opioid Use Disorder in Canada

Langlois J, Fairbairn N, Jutras-Aswad D, Le Foll B, Ahamad K, Lim R, Socías ME., Subst Use Addctn J. 2025

Trends in stimulant use among patients with opioid use disorder receiving substance use treatment: Findings from a prospective cohort study from 2013 to 2020

Jackson E, Bach P, Socias ME, Brooks OM, Fairbairn N, Rodrigues M, Rosic T, Naji L, Jinks-Chang S, Nolan S, Chesney A, Reshetukha T, Samaan Z, Dennis BB., Drug Alcohol Depend. 2025